Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) to Post Q3 2024 Earnings of ($0.24) Per Share, Leerink Partnrs Forecasts

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) – Investment analysts at Leerink Partnrs decreased their Q3 2024 earnings per share (EPS) estimates for Bolt Biotherapeutics in a research report issued on Wednesday, August 14th. Leerink Partnrs analyst D. Graybosch now anticipates that the company will post earnings per share of ($0.24) for the quarter, down from their prior forecast of ($0.18). Leerink Partnrs currently has a “Hold” rating on the stock. The consensus estimate for Bolt Biotherapeutics’ current full-year earnings is ($1.40) per share. Leerink Partnrs also issued estimates for Bolt Biotherapeutics’ Q4 2024 earnings at ($0.26) EPS, FY2024 earnings at ($1.34) EPS, FY2025 earnings at ($1.07) EPS, FY2026 earnings at ($0.47) EPS, FY2027 earnings at ($0.42) EPS and FY2028 earnings at ($0.31) EPS.

Bolt Biotherapeutics (NASDAQ:BOLT) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.08). The firm had revenue of $1.28 million for the quarter, compared to analyst estimates of $1.19 million. Bolt Biotherapeutics had a negative return on equity of 51.74% and a negative net margin of 556.59%.

Other research analysts also recently issued reports about the company. HC Wainwright reiterated a “neutral” rating on shares of Bolt Biotherapeutics in a report on Thursday. Guggenheim reiterated a “neutral” rating on shares of Bolt Biotherapeutics in a research note on Wednesday, May 15th. Stifel Nicolaus reissued a “hold” rating and issued a $1.50 price target (down from $6.00) on shares of Bolt Biotherapeutics in a research note on Wednesday, May 15th. Finally, SVB Leerink restated a “market perform” rating and issued a $1.00 price target (down previously from $3.00) on shares of Bolt Biotherapeutics in a report on Wednesday, May 15th. Five equities research analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $3.50.

Bolt Biotherapeutics Stock Performance

Shares of BOLT opened at $0.69 on Friday. Bolt Biotherapeutics has a 1 year low of $0.65 and a 1 year high of $1.56. The company’s 50 day simple moving average is $0.73 and its 200 day simple moving average is $0.98. The company has a market capitalization of $26.46 million, a price-to-earnings ratio of -0.42 and a beta of 0.94. The company has a debt-to-equity ratio of 0.16, a quick ratio of 5.68 and a current ratio of 5.68.

Institutional Trading of Bolt Biotherapeutics

A hedge fund recently bought a new stake in Bolt Biotherapeutics stock. Assenagon Asset Management S.A. bought a new stake in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 34,488 shares of the company’s stock, valued at approximately $26,000. Assenagon Asset Management S.A. owned about 0.09% of Bolt Biotherapeutics at the end of the most recent quarter. 86.70% of the stock is currently owned by institutional investors and hedge funds.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.